A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma Clinical trials frequently ...
Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point. The phase 3 trial found that adding chemotherapy to gefitinib improved PFS ...
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 Patients at 53 sites in China were randomly assigned 1:1 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results